Navigation Links
Pharsight Invited to Present on Modeling and Simulation at ARCS Australia Scientific Congress

Dr. Helen Kastrissios Will Present on Communicating the Value of

Pharmacodynamic Modeling in Clinical Drug Development

MOUNTAIN VIEW, Calif., May 27 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Helen Kastrissios, Ph.D., senior scientist, Pharsight Strategic Consulting Services, has been invited to present to clinical and regulatory professionals attending the Association of Regulatory and Clinical Scientists (ARCS) 17th Annual Congress. The Congress will be held at the Sydney Convention and Exhibition Centre in Sydney, Australia from May 28-30, 2008. Dr. Kastrissios will present on May 30, joining other leading experts from the pharmaceutical industry and academia in a session on clinical applications of pharmacodynamic modeling in drug development.

Dr. Kastrissios' presentation, entitled "Communicating the Value of Pharmacodynamic Modeling in Drug Development," will include several case studies describing how predictive drug-disease models have been used to support dose selection, compare the product profile of a new drug versus marketed competitors utilizing public-source literature data, and communicate model-based results to clinical project teams to support program decision- making. Presentation slides from Dr. Kastrissios' talk will be available at following the ARCS Congress.

"Model-based drug development has significant value for optimizing drug therapy and for improving the confidence of drug development decisions," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "Drug development teams can benefit from the quantitative application of drug-disease models to simulate expected clinical responses of new compounds, to support critical program strategies and enhance study design decisions. Pharsight is pleased to participate at the ARCS Congress, where we look forward to sharing our perspective with industry colleagues on the strategic use of modeling and simulation to improve drug development knowledge, productivity and decision- making."

Further information on the ARCS Congress can be found at

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trademarks of their respective companies or organizations.

SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Pharsight Invited to Present on Antiviral Modeling and Simulation at DIA Adherence Workshop
2. Pharsight Strengthens Senior Management Team
3. Pharsight Announces Fiscal Fourth Quarter 2008 and Year End Earnings Release Date and Conference Call
4. Pharsight Signs New Diabetes Meta-Database Customer
5. Pharsight to Present at eClinical Forum
6. Pharsight to Host Webinar on Hepatitis C Virus (HCV) and HIV Drug-Disease Modeling
7. FDA and Pharsight Continue to Collaborate Under CRADA
8. Pharsight to Present at DIA Cardiac Safety Conference on December 4, 2007
9. Pharsight Achieves $7.3 Million in Quarterly Revenue
10. Pharsight Expands Global Consulting Services Teams
11. Pharsight to Host European Software Conference
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent ... sharing, the 2016 Building Better Radiology Marketing Programs meeting will showcase ... Sunday, March 6, 2016, at Caesars Palace in Las Vegas with a pre-conference ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment ... itself for not only fulfilling the needs of advisers and clients but going ... price and providing top-tier customer service. However, there's always room for improvement, which ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... largest, most successful and prominent nonprofit healthcare organizations in the country. They have ... with various organizations, and helped advance the healthcare industry as a whole through ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., ... the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 ... brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive not ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... real-time eReferral system for diagnostic imaging in the Waterloo region. Using the Ocean ... Nuclear Medicine tests directly from their electronic medical record (EMR) without the need ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 26, 2015  The total global healthcare industry ... over 2015-2016. Latin America has the ... , (excluding Japan ), is second with ... continues to face increased healthcare expenditure. In 2013-2014, total government ... from 43.5% in 2008-2009 to 41.2% in 2013-2014. In real ...
(Date:11/25/2015)... N.C. , Nov. 25, 2015 ... the planned investment of at least $15.8  Million ... Wilmington, NC . The expansion ... capacity to meet the growing demands of the ... site expansion will provide up to ...
(Date:11/25/2015)... AVIV, Israel , November 25, 2015 ... (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical company ... simultaneous treatment of various clinical conditions, today announced the ... 3,158,900 American Depository Shares ( ADSs ), each representing ... purchase up to 3,158,900 ADSs. The ADSs and warrants ...
Breaking Medicine Technology: